Buying Research Peptides in the USA: A Procurement Guide for Laboratories
Most guides to buying research peptides are ranked vendor lists. They are close to useless, because the ranking almost always reduces to price per milligram, and price per milligram is the one specification that tells you least about what arrives at the bench.
This is a procurement guide instead. It covers what to verify before a purchase order goes out, what the documentation should actually contain, why domestic stock in the United States has become a materially different proposition than it was three years ago, and how to compare two suppliers who both claim 99% purity.
Start with the question the price tag cannot answer
A vial listed at 10 mg for $69 and a vial listed at 10 mg for $41 look like the same product at two prices. They usually are not, and the gap is rarely fraud. It is normally the difference between three things that a listing price does not disclose.
Chromatographic purity is not net peptide content. Reverse-phase HPLC reports the fraction of total peak area attributable to the target peak. It is a relative measure. It says nothing about how much of the powder in the vial is peptide as opposed to water, salt or counterion. Synthetic peptides purified by RP-HPLC are typically isolated as trifluoroacetate salts, and residual TFA can account for a meaningful percentage of the dry mass. Add adsorbed water — lyophilized peptide is hygroscopic, and Karl Fischer titration commonly returns several percent — and a vial that is genuinely 99% pure by area can still deliver considerably less peptide by mass than the label implies. Two vials at the same nominal fill can differ in delivered peptide by double digits without either certificate being wrong.
Fill accuracy is a separate measurement. Content uniformity across a filling run is not guaranteed by a purity assay on the bulk. A certificate reporting bulk purity but silent on the fill describes the powder before it was divided.
Identity confirmation is frequently absent. Purity tells you one species dominates the chromatogram. It does not tell you the species is the peptide you ordered. Mass spectrometry — LC-MS/MS or MALDI-TOF — confirms the molecular weight matches the intended sequence. A certificate with a purity number and no mass confirmation has verified homogeneity without verifying identity.
When comparing suppliers, the honest comparison is cost per milligram of confirmed net peptide, against a certificate that reports purity, identity, water content and counterion. Anything less is comparing two numbers that were not measured the same way.
What a usable certificate of analysis contains
A certificate that is doing its job carries, at minimum:
- The lot number that is physically printed on the vial you received. Not a representative certificate. Not a certificate for the compound generally. If the number on the paper does not match the number on the label, the document is describing different material.
- The stated fill mass, matching the listing. A certificate for a 5 mg fill against a listing that advertises 10 mg is a mismatch that no discount corrects.
- Purity by RP-HPLC, with the method and column conditions stated.
- Identity by mass spectrometry, with the observed and theoretical molecular weight.
- Water content, ideally by Karl Fischer titration.
- Residual counterion content, typically TFA or acetate.
- The name of the laboratory that performed the testing, and the date it was performed.
Two optional additions separate careful suppliers from adequate ones: endotoxin testing (LAL or recombinant Factor C) where the material is destined for cell culture, and residual solvent analysis by headspace GC. Endotoxin matters more than most buyers realize — sub-nanogram contamination perturbs cytokine readouts long before it is visible anywhere else, and the resulting artifact looks like a real effect.
Third-party testing versus self-reported numbers
In-house testing is not fraudulent. It is testing performed by the party with a commercial interest in the result. Independent confirmation exists because that structural conflict is real, and because analytical drift between laboratories is real even when everyone acts in good faith — interlaboratory purity comparisons on the same reference material routinely spread by more than a point.
The practical question is not “does this supplier test?” — nearly all claim to. It is “can I see who tested, when, and by what method?” A certificate naming its testing laboratory can be checked. A PDF with a logo and a number cannot.
Why domestic stock changed from a convenience to a requirement
Until roughly 2024, buying internationally was a cost decision with a lead-time penalty attached. For US laboratories in 2026, it is a different calculation, because the border has become an active variable.
The US International Trade Commission issued a General Exclusion Order in January 2025 restricting importation of tirzepatide material found to infringe Eli Lilly’s trademark. Exclusion orders operate at the point of entry and reach beyond the specific respondents named in the underlying complaint. Separately, FDA’s enforcement activity through 2025 — including more than fifty warning letters issued to GLP-1 compounders and manufacturers in September 2025, most dated September 9 — has made the category a focus of attention at the border as well as in the market.
The consequences are concrete:
- An indefinite hold is not a delay you can plan around. A detained shipment has no service-level agreement. Schedules that assumed a four-week transit absorb an unbounded one.
- Cold-chain exposure compounds. Lyophilized peptide is more forgiving than solution, but not indifferent. Extended ambient storage in an inspection queue is uncontrolled storage.
- Recovery is limited. A refund from an overseas seller replaces the money, not the timeline.
Material already inside the United States, already cleared, held by an identifiable domestic entity, removes that variable entirely. That is the whole argument for domestic sourcing, and it is sufficient on its own.
The supplier questions worth asking before the first order
Where does the material physically ship from? A named US address is verifiable. “Ships from the USA” as a badge, with no location behind it, frequently means a domestic mail-forwarding step in front of an offshore origin.
What entity am I buying from? A registered US entity with an address on file is answerable. An anonymous storefront is not.
Is there a batch COA on every listing, before purchase? Certificates furnished only after payment, or only on request, are a policy choice. The choice tells you something.
How does the supplier write about its products? This is the question buyers skip, and it is the strongest available predictor of whether a supplier is still operating a year from now. The federal warning letters issued across December 2024 and September 2025 targeted representations — efficacy claims, equivalence claims, human-facing instructions — far more than they targeted chemistry. A research supplier publishing administration guidance or outcome claims has demonstrated the exact behavior that draws enforcement. Continuity of supply is part of what you are buying, and copy discipline is a legible proxy for it.
Is the catalog supportable? A supplier listing two hundred compounds is not testing two hundred compounds to the same standard. A narrow, fully documented catalog is the stronger signal.
How Maple Research Labs is set up
The Maple Research Labs US store operates as a separate property from the Canadian store, under a Wyoming entity, with fulfillment handled in-house from Santa Barbara, California. There is no third-party logistics intermediary; orders are picked, packed and labeled by the same operation that holds the inventory, and orders placed on a business day ship the same day. Stock is purchased domestically after customs clearance, which is why an order does not sit in an import queue.
The catalog is fifteen compounds. Each one carries a batch-specific certificate of analysis linked on its product page, and a compound without a current batch COA is not published — including compounds that would otherwise sell. Items that signal human-administration intent are excluded on purpose: bacteriostatic water, syringes, alcohol prep pads and multi-compound convenience bundles are not stocked. Co-formulated blends remain, because a blend is a single vial with a single certificate rather than two products packaged together.
Each listed compound has a published preclinical literature base. Thymosin β4 was characterized as an actin-sequestering protein by Goldstein and Kleinman, with cardiac repair effects reported in mouse models by Bock-Marquette et al. in Nature (2004) and endothelial cell migration effects described by Malinda et al. BPC-157 has been studied across a long series of rat models by Sikirić and colleagues, including Achilles tendon transection work (Staresinic et al., Journal of Orthopaedic Research, 2003). GHK-Cu coordination chemistry and gene-expression profiling trace to Pickart’s work. Ipamorelin’s selectivity as a growth hormone secretagogue was described by Raun et al. in the European Journal of Endocrinology (1998) in rat and swine models. Tirzepatide’s dual GIP/GLP-1 receptor pharmacology was reported by Coskun et al. in Molecular Metabolism (2018), and the triple agonist retatrutide (LY3437943) by Coskun et al. in Cell Metabolism (2022), both characterized in rodent models and in vitro receptor systems. MOTS-c and AMPK activation were described by Lee et al. in Cell Metabolism (2015). Every one of those findings belongs to the animal model or cell system in which it was observed, and does not extend past it.
To see how a certificate is presented before committing to an order, start with TB-500 10mg with batch certificate of analysis, or compare it against BPC-157 10mg and the GHK-Cu 50mg listing. The full catalog is at the shop, and the analytical standards behind the certificates are set out on the lab testing page.
A short procurement checklist
- Confirm the listing shows a batch COA before purchase, not after.
- Confirm the lot number on the certificate matches the vial when it arrives.
- Confirm the certificate reports identity by mass spectrometry, not purity alone.
- Confirm the stated fill mass on the certificate matches the listing.
- Confirm water content and counterion are reported, and calculate net peptide content rather than trusting the nominal fill.
- Confirm the ship-from location and the legal entity.
- Archive every certificate locally at receipt. Do not rely on a vendor-hosted link remaining live.
- Record lot numbers against experiments, not supplier names.
Point seven is the one laboratories learn the hard way. Certificates hosted on a supplier’s website disappear when the supplier does, and 2026 has demonstrated that suppliers in this sector do disappear.
All products supplied by Maple Research Labs are sold for laboratory research use only. They are not for human consumption, not for veterinary use, and not intended for diagnostic or therapeutic application. All studies referenced above were conducted in animal models or in vitro systems and describe results in those systems only. Nothing on this page constitutes medical guidance.